GT Biopharma Inc
PAR:GTBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GT Biopharma Inc
PAR:GTBP
|
US |
|
W
|
Wendel SE
LSE:0HZD
|
FR |
|
Xiaomi Corp
OTC:XIACF
|
CN |
|
M
|
Macy's Inc
XBER:FDO
|
US |
|
Arcadis NV
OTC:ARCVF
|
NL |
|
K
|
Kandenko Co Ltd
F:5EY
|
JP |
|
M
|
Marathon Digital Holdings Inc
XBER:M44
|
US |
|
Helens International Holdings Co Ltd
HKEX:9869
|
CN |
|
A
|
Arthur J Gallagher & Co
LSE:0ITL
|
US |
|
Smooth Rock Ventures Corp
XTSX:SMRV
|
CA |
|
F
|
Fastly Inc
F:2Y7
|
US |
|
C
|
Caspian Sunrise PLC
XBER:RO1
|
UK |
|
M
|
Medios AG
LSE:0QB4
|
DE |
|
B
|
British American Tobacco PLC
SWB:BMT
|
UK |
|
Olam Group Ltd
F:K25
|
SG |
|
G
|
Gerresheimer AG
XMUN:GXI
|
DE |
|
Panasonic Holdings Corp
TSE:6752
|
JP |
|
Mitsui Fudosan Co Ltd
OTC:MTSFF
|
JP |
|
B
|
Boston Scientific Corp
XMUN:BSX
|
US |
|
Note AB (publ)
STO:NOTE
|
SE |
|
Travelzoo
NASDAQ:TZOO
|
US |
Bankruptcy Probability
GT Biopharma Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
GT Biopharma Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
GT Biopharma Inc
NASDAQ:GTBP
|
15.1m USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
384.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
181.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
167B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
65B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
GT Biopharma Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, GT Biopharma Inc has no debt.
You can find a full breakdown on its Balance Sheet.
